可切除非小细胞肺癌伴SMARCA4改变的免疫新辅助化疗
该回顾性研究分析了29例接受新辅助免疫化疗的SMARCA4改变NSCLC患者,客观缓解率70.4%,pCR率51.7%,鳞癌pCR率83.3%显著高于腺癌28.6%(p=0.045)。腺癌亚组中SMARCA4改变与早期进展相关,中位无事件生存期13个月,且KRAS与KEAP1/STK11共突变者全部复发。
要点
- SMARCA4改变NSCLC免疫新辅助化疗总体pCR率51.7%,鳞癌83.3%显著优于腺癌28.6%。
- 腺癌亚组中SMARCA4改变者42.8%早期进展,中位EFS 13个月。
- KRAS与KEAP1/STK11共突变患者全部复发,属免疫冷高风险亚型。
核心结论
- SMARCA4改变NSCLC异质性强,鳞癌对免疫化疗敏感,非鳞癌尤其KRAS+KEAP1/STK11共突变者为免疫冷高风险亚型。
研究设计与样本
- 回顾性分析29例接受新辅助免疫化疗的SMARCA4改变NSCLC患者的临床特征和二代测序。
- 利用TCGA肺腺癌全外显子测序数据按SMARCA4状态分组比较。
- 对SMARCA4改变组采用BostonGene分子功能肖像进行肿瘤免疫微环境分类。
主要发现
- 29例患者客观缓解率70.4%,pCR率51.7%。
- 鳞癌与腺癌pCR率分别为83.3%与28.6%,差异显著(p=0.045)。
- 中位随访17个月,7例复发,1例非癌死亡。
- 腺癌亚组SMARCA4改变与早期进展相关(42.8%),中位EFS 13个月。
- KRAS与KEAP1/STK11共突变患者全部复发。
关键数值与推荐
- TCGA数据中SMARCA4改变肺腺癌生存更差(34.8 vs 50.9个月,p=0.033)。
- SMARCA4改变组免疫细胞浸润缺乏者总生存显著短于免疫富集亚型(28.8 vs 49.9个月,p=0.043)。
临床怎么用
- SMARCA4改变NSCLC行新辅助免疫化疗前应区分组织学亚型,鳞癌可预期较高pCR。
- 腺癌伴SMARCA4改变尤其KRAS+KEAP1/STK11共突变者需警惕早期进展,考虑强化监测或替代策略。
局限性
- 回顾性单中心研究,样本量仅29例。
- 中位随访17个月较短,生存数据不成熟。
- TCGA分析为探索性,免疫微环境分类需前瞻验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neoadjuvant immunochemotherapy has improved pathologic complete response (pCR) rates and event-free survival in resectable NSCLC, yet its efficacy in SMARCA4-altered NSCLC, a subset associated with poor prognosis, remains unclear. METHODS: We retrospectively analyzed clinical characteristic and next-generation sequencing of 29 patients with SMARCA4-altered NSCLC who received neoadjuvant immunochemotherapy from Guangdong Provincial People's Hospital. The Cancer Genome Atlas of lung adenocarcinoma was classified through SMARCA4 condition by whole exome sequencing and further analyzed the difference between the two groups. In the altered group, BostonGene molecular functional portraits were used for tumor immune microenvironment classification. RESULTS: In general, 29 NSCLC patients with SMARCA4 alterations received neoadjuvant immunochemotherapy, the objective response rate was 70.4%, and the pCR rate was 51.7%. The pCR rate significantly differed among pathologic subgroups (squamous cell carcinoma [SCC] versus adenocarcinoma, 83.3% versus 28.6%, p = 0.045). After a median follow-up of 17 months, seven patients relapsed and one died from non-cancer causes. In adenocarcinoma subgroup, SMARCA4 alterations were associated with early progression (42.8%) with a median event-free survival of 13 months, although some patients achieved durable survival. All patients harboring co-occurring KRAS with KEAP1/STK11 mutations relapsed. The Cancer Genome Atlas data revealed that patients with SMARCA4-altered lung adenocarcinoma had worse survival (34.8 versus 50.9 mo, p = 0.033), down-regulation in innate immunity, and enrichment of mTOR/MYC signaling. Immune classification revealed both immune-desert and immune-enriched subtypes within the altered cohort. The lacking immune cell infiltration group had significantly shorter overall survival compared with the immune-enriched subtypes (28.8 versus 49.9 mo, p = 0.043). CONCLUSIONS: In conclusion, SMARCA4-altered NSCLC is heterogeneous. SCC demonstrates remarkable sensitivity with immunochemotherapy, but non-SCC, especially with KRAS+KEAP1/STK11 co-mutations, represents a distinct, immune-cold, high-risk subtype.
引用
- Peng LS, Cui Q, Zhang C, et al. Neoadjuvant Immunochemotherapy in Resectable NSCLC With SMARCA4 Alterations. J Thorac Oncol. 2025. PMID: 41161592. doi:10.1016/j.jtho.2025.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。